期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 12, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13045-019-0813-7
关键词
Chimeric antigen receptor T cells; Logic gate; Antigen escape; On-target; Off-tumor toxicities
资金
- National Natural Science Foundation of China [81830002, 31870873]
- National Key Research and Development Program of China [2016YFC1303501, 2016YFC1303504, 2017YFC0909803]
The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by antigen escape and on-target, off-tumor toxicities. Therefore, it may be a potentially effective strategy to select appropriate targets and to combine multi-antigen-targeted CAR-T cells with OR, AND and NOT Boolean logic gates. We summarize the current limitations of CAR-T cells as well as the efficacy and safety of logic-gated CAR-T cells in antitumor therapy. This review will help to explore more optimized strategies to expand the CAR-T cell therapeutic window.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据